Precision Stage 4 Cancer Treatment Options are one call away
Call Now
Early, Late-Stage, and Metastatic Stage 4 Cancer Treatment
Envita Medical Centers is a clinic of excellence for personalized oncology located in Scottsdale, Arizona. With
nearly
two decades of extensive experience treating late-stage, complex, and refractory-to-care cancer diagnoses, the experts
at Envita Medical Centers have found cancer to be a genetically and immunologically driven disease that can vary
widely
from patient to patient. While the standardized approach to cancer may be effective in the very early stages of
disease, it is all too common in later stage cancers to develop mutations and resistance that can evade chemotherapy.
The patients at Envita Medical Centers come to our clinic because they need a more detailed and tailored approach.
With
advanced precision testing and personalized targeted treatment selections, Envita can help to turn the tide in the
favor of late-stage and resistant cancer patients. The common phrase we here from our patients is, “I wish I would
have known about Envita sooner”.
Disclaimer: Individual results will vary. Envita makes no guarantees for outcomes. Each patient case is unique. Please
consult your doctor before making any changes to your medical treatment. Not every patient is a candidate for care or
achieves these results. Treatments used in this case may not all be FDA approved for the treatment of this condition.
Envita Medical Centers has helped thousands of metastatic cancer patients find amazing success by providing a
personalized
integrative approach. This starts with Envita’s genetic testing that goes beyond standard genomic cancer
analysis into the next level of highly detailed and precision targeted labs. With this highly comprehensive
information, Envita can custom build protocols to hit the most current and effective genetic and immunological
targets, strengthening the patient and their immune system. With superior, genetically targeted medicine and advanced
technology, Envita helps cancer patients outperform other facilities and gain valuable progress against late-stage and
complex cancers.
Precision Targeted, Multifaceted Approach to Stage 4 Cancer Treatment
Envita Medical Centers’s precision-targeted, patient-based cancer treatment modalities are designed to help patients
who have exhausted conventional medical and other natural treatment resources. We use a comprehensive treatment
strategy that focuses on addressing key factors in the development and circulation of cancer. The microenvironment
around the cancer, micro-satellite instability, epigenetics, and immuno-reactivity are crucial drivers in the growth
and spread of cancer and are essential targets in the development of Envita’s treatment protocols.
Your Cancer’s Microenvironment
Once a tumor reaches 2mm in diameter, it can no longer sustain itself and the cells within the tumor begin to produce
a signaling protein known as VEGF, or vascular endothelial growth factor. VEGF stimulates the formation of new,
irregular blood vessels around the tumor to feed it.
Once it gains a blood supply, the tumor can now grow exponentially, but more importantly, tumor cells can now break
off and travel within blood vessels to the far reaches of the body. This is known as metastasis and it is the leading
cause of death by cancer.
Through a process known as angiogenesis, growth factors like VEGFA can be regulated, blocking the tumors’ ability to
develop a blood supply [1]. Often the drugs selected to treat metastasis are limited to antiangiogenic medications
alone. Envita’s personalized treatment protocols work to decelerate or prevent metastasis by addressing the
microenvironment around your cancer. Our doctors can utilize antiangiogenic smart drug technology, alongside
customized integrative medicines, to silence cancerous blood vessel growth, thereby slowing the spread of circulating
cancer cells. Combining genetic targets and natural agents with comprehensive and highly detailed testing allows for
customized medication that focuses on the patient’s specific needs, making all the difference in care.
Microsatellite Instability
A second key factor that must be addressed is microsatellite instability. Microsatellite instabilities (MSI) are
defined as, “A change that occurs in certain cells (such as cancer cells) in which the number of repeated DNA bases in
a microsatellite (a short, repeated sequence of DNA) is different from what it was when the microsatellite was
inherited.”
In other words, MSI are thought to be the result of mutations that do not get corrected when DNA is copied inside of
a cell. This allows for the continued mutation of the cancerous cells, making treatment extremely difficult because of
constantly changing targets. Envita has next level testing to accurately measure these rates and deploy the correct
treatments to slow them down. It can be very important to accurately target your cancer because mutational rates can
be worsened by the wrong chemotherapy selection. Overcoming the mutational rate of the cancer is essential to
improving outcomes and powerfully impacting the cancer. Last month’s cancer is not today’s cancer; we know this at
Envita and have developed treatments to address microsatellite instability to help keep our patients one step ahead of
their disease.
Which is why at Envita Medical Centers we perform advanced genomic testing, utilizing next generation DNA sequencing
focused on circulating tumor cells, or CTCs. CTCs carry the most recently mutated form of a cancer’s genetic markers.
This advanced form of testing gives our doctors access to real-time data for creating an up-to-date customized medical
blueprint of a patient and their cancer’s genetic biomarkers. This true medical blueprint is combined with Envita’s
customized algorithms to precisely monitor and treat mutational rates, genomic targets, and immunotherapy targets. It
really all comes down to detailed precision and Envita provides the most customized treatment plan to target each
patient unique needs.
This true medical blueprint is continuously updated as our patient’s cancer targets change. Setting the foundation
for personalized treatment protocols that proactively target the most recent genetic markers. Envita targets these
genetic signatures with precision driven medications and therapy options designed specifically for that patient,
providing a greater chance at achieving success against the cancer.
Epigenetic Influences on Mutation
Our decades of clinical experience have lent us keen insight into other important epigenetic influences on cell
mutation and growth. Oncogenes and tumor suppressor genes can have a huge impact on the proliferation of cancers and
Envita has developed indispensable experience identifying and modulating these genes. Proto-oncogenes are genes that
normally help cells grow. When a proto-oncogene mutates, it can cause uncontrolled growth of the cell. These mutated
genes are called oncogenes. Adversely, tumor suppressor genes, as the name implies, are genes that slow down cell
division and repair DNA mistakes. They are also responsible for signaling apoptosis or programmed cell death.
Metastasis and tumor growth have been highly correlated with loss of tumor suppressor and oncogene regulation [4].
Cancerous cells have an abnormal balance of tumor suppression and oncogene expression [5]. Normally the body uses
these genes to regulate cell division and death. When they are disrupted though, cancerous cells can form [5]. In
time, these cells will work to gain a blood supply through the angiogenesis process and begin spreading throughout the
body. If miRNA is not addressed in treatment as soon as possible, the cancer can spread and become more and more
difficult to treat.
When these genes are mutated, cells can again grow out of control and lead to cancer. So, to affect the spread of
cancer on an epigenetic level, we must both “turn off” oncogenes and “turn on” tumor suppressor genes. And that is
exactly the epigenetic approach we take at Envita Medical Centers. Using MiRNA gene silencing, Envita treatment
protocols promote the downregulation of oncogenes and the upregulation of tumor suppressor genes, promoting apoptosis
of the cancerous cells.
There are thousands of different MiRNA variations; Envita’s advanced genomic testing of circulating tumor cells
allows for identification of MiRNA targets through next-generation DNA sequencing. With Envita’s customized algorithm,
we precision target the most recent mutations of that patient’s individual cancer. Combined with customized
integrative medications, Envita’s unique precision treatment protocols aim to aggressively downregulate oncogenes and
upregulate tumor suppressor genes. In this way we may initiate the body's natural defense against cancerous cells and
possibly halt the growth and spread of the disease.
Overcoming Suppressed Immuno-Reactivity
Still another hurdle to overcome when treating Stage 4 or late-stage cancers is suppressed immuno-reactivity, or the
immune system’s ability to identify and respond to that cancer. Many patients often have ravaged immune systems, not
only from their cancer or infections, but also from receiving failed high-dose chemotherapy and/or radiation
treatments.
A robust and healthy immune system has the capability to adapt dynamically and the immune system is recognized as
being integral in the fight against cancer [2]. As cancer cells mutate, a properly regulated immune system can
actively re-evaluate and respond to those mutations [2]. Studies have found that some metastatic cancer patients who
have not responded well to treatment, have found success with immunotherapy [3]. It is key to re-establishing
immunoreactivity for each unique patient.
Re-establishing immunoreactivity involves methods by which we can turn a cold tumor (a tumor that hasn’t been
recognized by or provoked a strong response in the immune system) into a hot tumor (one that has been swarmed by
T-cells, creating an inflamed tumor).
Neo-antigens are markers that signal the cancer cell and tumors to the immune system. Envita’s immunotherapy and
immunotherapy adjunctive options are designed to re-establish the immune system and potentially re-program it to
recognize the tumors’ neo-antigens and fight the cancer.
Advanced Customizable Therapies
Envita Medical Centers has developed many specialized proprietary therapies to personalize treatment options and
directly attack hard to reach and complex late-stage cancers. Dedicated treatments such as Genetically Targeted
Fractionated Chemotherapy (GTFC™), Chemo Immunotherapy Percutaneous Injections (CIPI™), and Autologous Adoptive
Immunotherapy (AAIT) are just a few of the techniques and strategies that Envita’s physicians utilize to build
advanced customized treatment protocols.
Genetically Targeted Fractionated Chemotherapy
Genetically Targeted Fractionated Chemotherapy, or GTFC™, is a personalized form of cancer treatment that uses
genetic
data, cancer biomarkers, and molecular targets to determine the potentially most effective patient-specific
chemotherapies and immunotherapy agents. Through advanced genomic testing, GTFC™ precision targets a patient’s unique
genetic markers and cancer chemo sensitivities. This data is continuously updated and analyzed by our expert
physicians to dynamically tailor GTFC™ and other treatment option for each patient. To ensuring that each treatment is
adapted to the patient’s personal combination of genetic targets, GTFC™, and all Envita’s custom compounded IVs, are
created in our in-house pharmacy.
Disclaimer: Individual results will vary. Envita makes no guarantees for outcomes. Each patient case is unique. Please
consult your doctor before making any changes to your medical treatment. Not every patient is a candidate for care or
achieves these results. Treatments used in this case may not all be FDA approved for the treatment of this condition.
This precision targeted method can minimize the dosage needed to achieve tumor kill, effectively working to maximize
the effectiveness of chemotherapy while possibly reducing the chances for negative side-effects. At Envita, we take a
more advanced approach. By combining GTFC™ with natural, research-based therapies, immunotherapies, and many other
world-class treatments, we can provide a multifaceted personalized approach to treating cancer that is truly unique to
our clinic.
A new form of tumor chemoembolization called Chemo Immunotherapy Percutaneous Injections,
or CIPI™, is an advanced treatment method for fibrous tumors that are difficult to penetrate through traditional
intravenous chemotherapy treatment. By combining our unique personalized treatment protocols with the accuracy and
increased precision of direct injection interventional radiology, we are approaching a new frontier in cancer
treatment.
This video is for informational purposes only. Individual results will vary. Envita makes no guarantees.
Consult with your doctor to see if CIPI™ is right for you. Not every patient is a candidate for Chemo Immuno
Precision Injection. Some cancers may not have actionable biomarkers or molecular profiles. Do not alter
your medical care based on any information provided in this video. Please, consult your doctor prior to
changing or stopping any current medical treatment you are receiving.
CIPI™ is a targeted, minimally invasive option for cancer patients who are unable to undergo surgical tumor. The
CIPI™ procedure is designed for cancers that originate in dense tissues that traditional intravenous chemotherapy has
been ineffective penetrating, like pancreatic and liver cancer. CIPI™ is a procedure performed through interventional
radiology that allows for precise delivery of personalized genetically targeted medications directly into the
cancerous tumors. By directly injecting medications into the tumor we can potentially achieve maximum exposure of the
genetically targeted medications to the tumor, making it a very powerful method of targeted treatment delivery.
Autologous Adoptive Immunotherapy (AAIT)
Autologous
Adoptive Immunotherapy (AAIT) is a type of therapy that is
only available in our Mexico center and is not approved by the FDA for the treatment of cancer within the United
States. AAIT utilizes a targeted natural killer cell treatment using the patient's own immune system.
With nearly a decade of experience in treating the most difficult cancers, we have developed one of the most
innovative immune-based cancer treatment therapies in existence. AAIT is our proprietary method of helping cancer
patients achieve stronger immune systems by supplementing their bodies with healthy immune cells that have the ability
to fight cancer. In essence, AAIT is akin to an immune system transplant. However, unlike organ transplants, in which
organs are obtained from one person and given to another, the cells that are transplanted in the AAIT process are
autologous, which means they are the patient's own cells.
Disclaimer: Individual results will vary. Envita makes no guarantees for outcomes. Each patient case is unique. Please
consult your doctor before making any changes to your medical treatment. Not every patient is a candidate for care or
achieves these results. Treatments used in this case may not all be FDA approved for the treatment of this condition.
Conclusion
Envita Medical Centers has spent the last two decades treating the most resistant and aggressive late-stage cancers.
We have helped thousands of cancer patients from all around the world, including many stage four cancers patients,
find real progression against their condition. Many patients finish their treatment at Envita and wish they would have
found us sooner but are still grateful to have experienced the amazing healing that happens at our center.
Our goal is to provide the best possible chance for our patients to positively progress against their disease. We
combine the best research based integrative and conventional therapies from around the world with cutting-edge genetic
testing, to build completely customized genetically targeted protocols for each individual patients’ unique needs. By
going above and beyond the standard level of care, we hope to help our patients achieve success where other facilities
have failed. If you have any questions about metastasis or your specific cancer treatment, please contact our Patient
Care Coordinators at 866-830-4576 and learn more about Envita’s unique approach to cancer.
Recommended Videos
Causes of Cancer
Next-Generation Precision Immunotherapy Options
References
[1] Kawagishi, H., et al., ARF Suppresses Tumor Angiogenesis through Translational Control of VEGFA
mRNA. 2010. 70(11): p. 4749-4758
[2] NIH. Cancer Stat Facts: Common Cancer Sites. 2019 [cited 2020 2/14]; Available from:
https://seer.cancer.gov/statfacts/html/common.html.
[3] Balogh, E., Policy issues in the clinical development and use of immunotherapy for cancer treatment. National
Cancer Policy Forum, Board on Health Care Services, Health and Medicine Division, The National Academies of
Sciences, Engineering, Medicine, ed. K. Maxfield, et al. 2016: Washington, DC : National Academies Press.
[4] Levine, A.J. and A.M. Puzio-Kuter, The Control of the Metabolic Switch in Cancers by Oncogenes and Tumor
Suppressor Genes. 2010. 330(6009): p. 1340-1344
[5] Lodish H, B.A., Zipursky SL, Proto-Oncogenes and Tumor-Suppressor Genes. Molecular Cell Biology. Vol. 4th
edition. 2000, New York: W. H. Freeman.
Choose Envita Medical Centers
Our team is ready to help you get your life back! Please enter your contact information and a Patient Care
Expert will contact you shortly. If you would rather speak now, please give us a call at 1-866-830-4576.
